Eligibility for Nirmatrelvir/Ritonavir Among Adults With an Acute Care COVID ‐19 Encounter: A Retrospective Cohort Study From Alberta, Canada
Pharmacoepidemiology and Drug Safety · 2026
DOI: 10.1002/pds.70302 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von Sylvia Aponte-Hao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Data and Research Services, Alberta SPOR SUPPORT Unit Data Platform, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Ritonavir, COVID-19 Drug Treatment, COVID-19, Antiviral Agents. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer-Alberta Collaboration in Health.
Abstract (Originalsprache)
Purpose
To describe the characteristics of adults who had a severe coronavirus disease 2019 (COVID‐19) outcome during a timeframe that nirmatrelvir/ritonavir (NMV‐r; Paxlovid) was available, to assess medical eligibility and receipt of NMV‐r before presentation to acute care.
Methods
Population‐level administrative data was used to describe adults (≥ 18 years) who had an acute care COVID‐19 encounter (hospitalization or emergency department visit with COVID‐19) between January 2022 and March 2023 in Alberta, Canada.
Results
The 30 793 adults had an acute care COVID‐19 encounter; among the 8345 (27.1%) who were assessed as medically eligible for NMV‐r, 8111 (97.2%) did not receive outpatient NMV‐ r ≤ 30 days before the encounter. During the acute care COVID‐19 encounter, the proportion who had an all‐cause death was 4.7% (received prior NMV‐r treatment) and 6.6% (did not) among those who were medically eligible for NMV‐r. Of those medically eligible for NMV‐r who were hospitalized ( n = 4495), the mean length of stay was 9.7 days (SD 11.1) in NMV‐r treated and 15.3 days (SD 25.9) in untreated, and the proportion admitted to the intensive care unit was 2.1% in NMV‐r treated and 7.6% in untreated.
Conclusion
Results from this real‐world study show that most adults with an acute care COVID‐19 encounter who were assessed as medically eligible for NMV‐r at the time of presentation had not received this outpatient treatment beforehand in Alberta, Canada, suggesting a potential care gap. If gaps are closed, strain on the acute healthcare system can be alleviated, with attendant improvement in other important patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Data and Research Services, Alberta SPOR SUPPORT Unit Data Platform, Calgary, Alberta, Canada.
- Real World Evidence Unit, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
- Centre for Health Informatics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
- Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
- Department of Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada.
- Infection Prevention and Control, Alberta Health Services, Edmonton, Alberta, Canada.
ORCID-Profile: Sylvia Aponte-Hao, Khanh Vu, Jason R Randall, Karen J B Martins, Phuong Uyen Nguyen, Jenine Leal, Elissa Rennert-May, Ellen Rafferty, Tyler Williamson, Scott W Klarenbach
Förderung
- Pfizer-Alberta Collaboration in Health
Zitieren
APA
Aponte-Hao, S., Vu, K., Randall, J. R., Martins, K. J. B., Nguyen, P. U., Saxinger, L., Leal, J., Rennert-May, E., Rafferty, E., Williamson, T., & Klarenbach, S. W. (2026). Eligibility for Nirmatrelvir/Ritonavir Among Adults With an Acute Care COVID ‐19 Encounter: A Retrospective Cohort Study From Alberta, Canada. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70302
Vancouver
Aponte-Hao S, Vu K, Randall JR, Martins KJB, Nguyen PU, Saxinger L, et al. Eligibility for Nirmatrelvir/Ritonavir Among Adults With an Acute Care COVID ‐19 Encounter: A Retrospective Cohort Study From Alberta, Canada. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70302
BibTeX
@article{AponteHao2026,
author = {Aponte-Hao, Sylvia and Vu, Khanh and Randall, Jason R and Martins, Karen J B and Nguyen, Phuong Uyen and Saxinger, Lynora and Leal, Jenine and Rennert-May, Elissa and Rafferty, Ellen and Williamson, Tyler and Klarenbach, Scott W},
title = {Eligibility for Nirmatrelvir/Ritonavir Among Adults With an Acute Care COVID ‐19 Encounter: A Retrospective Cohort Study From Alberta, Canada},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
doi = {10.1002/pds.70302}
}
EUVIMED